SERODIAGNOSIS AND IMMUNOPROPHYLAXIS OF AMEBIASIS

阿米巴病的血清学诊断和免疫预防

• 批准号: 2538212
• 负责人: David M. Lyerly
• 金额: $ 33.85万
• 依托单位: TECHLAB, INC.
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-01 至 2000-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2538212
• 关键词: SERODIAGNOSIS; IMMUNOPROPHYLAXIS; AMEBIASIS

DESCRIPTION (Adapted from the Applicant's Abstract): The trophozoites of Entamoeba histolytica, the cause of human amebiasis adhere to colonic mucins, intestinal epithelium and leukocytes via a galactose-specific lectin. The lectin is a major conserved surface antigen which is recognized by the immune sera of 99 percent of tested patients with amebic liver abscess and colitis. Inhibition of this lectin with galactose prevents adherence and contact- dependent killing of immune effector cells such as neutrophils and macrophages. The lectin also mediates amebic resistance to the human complement membrane attack complex. Preliminary evidence indicate that the recombinant-expressed lectin is a more specific serodiagnostic reagent for acute amebiasis. In addition, the recombinant lectin is a protective antigen in an animal model of amebiasis. Dr. Lyerly proposes the development a more specific EIA for serodiagnosis of amebiasis using recombinant expressed amebic adherence lectin. Experience acquired in expression of fragments of the lectin gene for the EIA will be applied towards future development of a vaccine against amebiasis..

说明（改编自申请人的摘要）：滋养体 溶组织内阿米巴是引起人类阿米巴病的主要病原体， 粘蛋白、肠上皮细胞和白细胞通过半乳糖特异性 凝集素。凝集素是一种主要的保守表面抗原， 被99%的受试患者的免疫血清所识别， 阿米巴肝脓肿和结肠炎。抑制这种凝集素， 半乳糖阻止免疫粘附和接触依赖性杀伤 效应细胞如嗜中性粒细胞和巨噬细胞。该凝集素还 介导阿米巴对人补体膜攻击的抗性 复杂.初步证据表明， 凝集素是一种特异性较强的急性阿米巴病血清学诊断试剂。 此外，重组凝集素是动物中的保护性抗原 阿米巴病模型。 博士Lyerly建议开发一种更特异的EIA用于血清学诊断 使用重组表达的阿米巴粘附凝集素的阿米巴病。 外源凝集素基因片段表达的经验 EIA将应用于未来疫苗的开发， 阿米巴病